Related Experiment Video
Updated: Apr 3, 2026
08:32
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
23.5K
To beta block or not to beta block; that is the question
1Department of Intensive Care, Erasmus MC, University Medical Center, s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. c.ince@erasmusmc.nl.
Critical Care (London, England)
|September 25, 2015
Summary
Esmolol, a beta-blocker, may improve sepsis outcomes by normalizing heart rate and improving microcirculation. Further research is needed to confirm its survival benefit in sepsis patients.
Area of Science:
- Critical care medicine
- Pharmacology
- Sepsis research
Background:
- The beta-1 blocker esmolol has gained attention for potential sepsis survival benefits.
- Its mechanism of action in sepsis, particularly regarding microcirculation, remains debated.
Purpose of the Study:
- To investigate if esmolol corrects sepsis-induced microcirculatory alterations.
- To test the hypothesis that esmolol's heart rate reduction improves sublingual and gut microcirculation in sepsis.
Main Methods:
- Utilized a pig model of sepsis.
- Administered esmolol to reduce heart rate.
- Assessed sublingual and gut microcirculatory parameters.
Main Results:
- Esmolol administration corrected sepsis-induced alterations in sublingual and gut microcirculation.
- The study provides evidence for a potential mechanism of esmolol's benefit in sepsis.
Conclusions:
- Esmolol may improve sepsis outcomes by positively impacting microcirculatory function.
- These findings warrant further investigation into esmolol's role in sepsis treatment.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:17Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K